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Abstract: Malaria is of continuing concern in nonimmune traveling populations. Traditionally, 
antimalarial drugs have been developed as agents for dual indications (treatment and prophy-
laxis). However, since 2000, when the 5th Amendment to the Declaration of Helsinki (DH2000) 
was adopted, development of new malaria prophylaxis drugs in this manner has ceased. As a 
consequence, there may not be any new drugs licensed for this indication in the foreseeable 
future. Major pharmaceutical companies have interpreted DH2000 to mean that the traditional 
development paradigm may be considered unethical because of doubt over the likelihood of 
beneﬁ  t to endemic populations participating in clinical studies, the use of placebo, and the 
sustainability of post-trial access to study medications. In this article, we explore the basis of 
these concerns and suggest that the traditional development paradigm remains ethical under 
certain circumstances. We also consider alternative approaches that may be more attractive to 
sponsors as they either do not use placebo, or utilize populations in endemic countries who 
may unambiguously beneﬁ  t. These approaches represent the way forward in the future, but are 
at present unproven in clinical practice, and face numerous regulatory, logistical and technical 
challenges. Consequently, in the short term, we argue that the traditional clinical development 
paradigm remains the most feasible approach and is ethical and consistent with the spirit of 
DH2000 under the appropriate circumstances.
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Introduction
Malaria is caused by four parasitic protozoa of the genus Plasmodium (P. falciparum, 
P. vivax, P. ovale, and P. malariae). The disease is prevalent in most tropical regions, 
causing up to 500 million clinical cases, and over one million deaths per year, mostly 
in children (WHO 2005). In areas of high transmission, continuous exposure to malaria 
confers partial or ‘semi-immunity’. There are also smaller but growing populations of 
nonimmunes in endemic countries (UNFPA 2007). Each year, 25–30 million nonim-
mune people travel from nonendemic to endemic countries for holidays, business, 
military deployments, or to visit friends and relatives (Chen and Keystone 2005). 
Malaria imported by this population upon their return is a signiﬁ  cant public health 
concern, with approximately 30000 cases a year and fatality rates ranging from 1%–4% 
(Muentener et al 1999; Magill 2004; Newman et al 2004; Chen and Keystone 2005; 
Christen et al 2006; Legros et al 2007). There are, in traditional thinking, two distinct 
populations that may beneﬁ  t from the development of new antimalarial drugs. The 
populations of endemic countries beneﬁ  t from drugs to treat symptomatic malaria, 
while the nonimmune traveling population in nonendemic countries (the traditional 
target population) beneﬁ  t from drugs for malaria prevention. However, there is a 
growing realization that drugs with malaria prophylaxis properties can also potentially Therapeutics and Clinical Risk Management 2008:4(4) 804
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beneﬁ  t nonimmune travelers from endemic countries, infants, 
children, and pregnant women through intermittent presump-
tive treatment, and everyone living in endemic countries in 
the context of malaria control (USAID 2007) and potential 
elimination (Bill and Melinda Gates Foundation 2007).
Prophylactic antimalarials work by either disrupting the 
initial development of malaria parasites in the liver (causal 
activity), suppressing the emergent asexual blood stages of 
the parasite (suppressive activity) or preventing the relapses 
induced by the latent liver forms (hypnozoites) of relaps-
ing P. vivax and P. ovale malaria (presumptive antirelapse 
therapy or PART; see reviews by Hill et al 2006; USCDC 
2008). At least three prophylaxis strategies of administration 
have been utilized to exploit these properties. The most com-
mon approach is to administer causal or suppressive drugs 
at efﬁ  cacious prophylaxis (subtherapeutic) doses continu-
ously throughout the period of exposure to malaria (Baird 
et al 2007). For prophylactic drugs, with the exception of 
primaquine, a post-exposure PART regime is required to 
prevent subsequent relapse of P. vivax (Hill et al 2006). An 
alternative approach is so called ‘ﬁ  re and forget’ prophy-
laxis, or ‘pre-exposure prophylaxis’, in which travelers are 
given a single dose or short course regime of a long half-life 
drug at a treatment dose that will protect throughout the 
duration of exposure (Shanks et al 2007). This approach is 
currently unproven in clinical practice, although some drugs 
have the potential to be used in this manner (tafenoquine, 
atovaquone-proguanil and piperaquine). As we shall see, no 
drug for malaria prevention is adequate in all respects. There 
is therefore a need to develop new drugs for this indication. 
However, no new drugs for malaria prophylaxis have been 
approved in the United States since 2000, despite three 
(meﬂ  oquine, atovaquone-proguanil, and doxycycline) hav-
ing been licensed in the preceding decade. This has occurred 
as a direct consequence of ethical concerns raised by major 
pharmaceutical companies in the wake of changes to the 
Declaration of Helsinki in 2000 (DH2000).
The Declaration of Helsinki (WMA 2004) is a statement 
of ethical principles adopted at the congress of the World 
Medical Association in 1964 (Carlson et al 2004). The intent 
of the declaration was to formalize a set of core principles 
for the ethical execution of medical research (Carlson et al 
2004). Prior to the DH, the only similar document was the 
Nuremburg Code (Carlson et al 2004). This was formal-
ized during the trial of Nazi doctors for war crimes in 1947 
(Kious 2001). The Nuremburg Code enshrined twelve ethi-
cal standards with which physicians should comply when 
conducting research involving human subjects, including 
informed consent and ensuring beneﬁ  t to study participants 
(discussed in Carlson et al 2004). The original Declaration of 
Helsinki embodied most of these ethical principles (Carlson 
et al 2004). The Declaration was modiﬁ  ed substantially in 
1975, and again to a lesser extent in 1983, 1989, and 1996 as 
international consensus shifted, or to provide greater clariﬁ  -
cation (Carlson et al 2004). The principles enshrined in the 
1975 amendment were arguably the most widely recognized 
source of ethical guidance for two and half decades (Carlson 
et al 2004). However the 5th Amendment, adopted in 2000 
(DH2000), has resulted in controversy in many areas of 
medical research (Forster et al 2001; Carlson et al 2004; Lie 
et al 2004). Ethical concerns relating to population beneﬁ  t, 
the use of placebo and the sustainability of post-trial access 
to study drugs have had a profound impact on the develop-
ment of new drugs for malaria prevention.
This review will describe existing and potential prophy-
lactic drugs, outline the traditional manner in which these 
drugs are developed, consider the DH2000-related ethical 
objections to the traditional development paradigm, argue 
that the traditional development paradigm remains ethical 
and consistent with the spirit of DH2000 under some cir-
cumstances, and outline alternative approaches that, while 
challenging now, may, if successful, circumvent DH2000-
related ethical concerns in the future. Finally, we argue that 
unless a pathway forward can be clearly deﬁ  ned, develop-
ment of new prophylaxis drugs will not be feasible in the 
foreseeable future.
Current and future prophylactic 
antimalarial drugs
Currently available drugs
Five commercially available antimalarials (discussed below) 
have been formally registered in the United States for malaria 
prevention (USCDC 2008; Table 1). The four drugs approved 
for continuous prophylaxis in the United States are meﬂ  o-
quine, atovaquone-proguanil, doxycycline, and chloroquine 
(USCDC 2008). Primaquine is approved for radical cure of 
P. vivax and P. ovale. It is recommended but not formally 
licensed for continuous prophylaxis (Hill et al 2006; USCDC 
2008). Fansidar (pyrimethamine-sulfadoxine) was previously 
indicated for prophylaxis in the United States, but is no longer 
used for this purpose due to its association with fatal Stevens-
Johnson syndrome (Miller 1986). To our knowledge, the only 
other drug approved elsewhere is chloroquine-proguanil. 
Several recent reviews have documented the beneﬁ  ts and lim-
itations of each of these (Milhous 2001; Shanks et al 2001a; Therapeutics and Clinical Risk Management 2008:4(4) 805
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Table 1 Characteristics of currently available drugs for malaria prevention
Drug Prophylaxis strategy 
(suppressive or causal)
Regimen Cost for 28 day 
exposure in 
$U.S. (Bryan 
2006)
Utility/resis-
tance concerns
Tolerability Utility against 
P. vivax
FDA-approved 
prophylaxis 
indications
Primaquine PART*/continuous (causal/
anti-relapse)
Daily 102 No resistance 
concerns at pres-
ent. Little intrinsic 
blood stage 
activity can lead 
to severe malaria 
rapidly if doses 
missed.
Contraindicated in 
G6PD deﬁ  ciency. 
GI upset is a 
problem in some 
patients. This can 
be mitigated if 
drug administered 
with food.
Exhibits causal 
and antihyp-
nozite activ-
ity. Useful as 
post-exposure 
prophylaxis for 
hypnozoites 
if given upon 
return from an 
endemic area.
Radical cure (pre-
vention of relapse) 
of P. vivax.
Meﬂ  oquine Continuous (suppressive) Weekly 106 Not useful on 
Thai borders.
Associated with 
adverse CNS 
events in some 
patients. Use 
justiﬁ  able on basis 
of risk-beneﬁ  t.
No activity 
against liver 
stages, therefore 
cannot prevent 
relapses. Sup-
presses blood 
stage infection.
Prevention of fal-
ciparum and vivax 
malaria.
Doxycycline Continuous (suppressive, 
partially causal)
Daily 15 None at present. Severe esophogitis 
rarely. GI upset 
is a problem in 
some patients, 
that is improved if 
drug administered 
with food. Some 
formulations are 
thought to be 
poorly tolerated, 
although there is 
no unambiguous 
clinical evidence of 
this. Contraindi-
cated for children 
or in pregnancy. 
Photosensitivity.
No activity 
against hypno-
zoites, therefore 
cannot prevent 
relapses. Sup-
presses blood 
stage infection.
Short term 
prevention of falci-
parum malaria.
Atovaquone-
proguanil
Continuous (suppressive/ 
causal)
Daily 182 Worldwide 
effectiveness but 
intrinsic capacity 
for resistance 
induction.
Lowest withdrawal 
rate amongst 
comparator 
regimens.
No activity 
against hypno-
zoites, therefore 
cannot prevent 
relapses.
Prevention of falci-
parum malaria.
Chloroquine Continuous (suppressive) Weekly 50 Not effective in 
most areas due 
to widespread 
resistance to 
chloroquine.
Higher withdrawal 
rate than com-
parator regimens 
when combined 
with proguanil.
No activity 
against liver 
stages, therefore 
cannot prevent 
relapses. Sup-
presses blood 
stage infection.
Prevention of 
susceptible strains 
of all Plasmodium 
spp.
Note: *Presumptive anti-relapse treatment (P. vivax); All information was obtained from recent reviews or from the sources indicated in the accompanying text.
Peterson 2004; Chen and Keystone 2005; Shanks and Edstein 
2005; Hill et al 2006; Baird et al 2007; Chen et al 2006), and 
the US Centers for Disease Control publishes prescribing 
information on a biannual basis (USCDC 2008). Summary 
information is outlined in Table 1. The utility of each drug 
can be rated in terms of cost, safety/tolerability, potential for 
compliance, activity against multiply-drug resistant strains 
of malaria, efﬁ  cacy against P. vivax and regulatory status. Therapeutics and Clinical Risk Management 2008:4(4) 806
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None of the available choices are perfect, so there is a clear 
case for the development of alternatives.
Prophylactic drugs in clinical development
The only compound in formal clinical development for 
prophylaxis is tafenoquine. Tafenoquine is a primaquine 
analog with a much longer half-life that exhibits activity as 
a suppressive, causal, and antirelapse prophylactic drug, and 
that in a continuous prophylaxis mode can be administered 
once weekly or monthly (Brueckner et al 1998a, 1998b, 2001; 
Peters 1999; Walsh et al 1999; Lell et al 2000; Shanks et al 
2001b; Nasveld et al 2002b; Hale et al 2003; Walsh et al 
2004). Tafenoquine might also potentially be administered in 
a ‘pre-exposure prophylaxis’ mode (Shanks et al 2001b; Hale 
et al 2003). Like primaquine, tafenoquine also has the disad-
vantage of causing hemolysis in G6PD deﬁ  ciency (Shanks 
and Edstein 2005; Brueckner et al 2001). Unfortunately the 
development of tafenoquine for prophylaxis has been sub-
stantially delayed in favor of a new indication: radical cure 
(treatment) of P. vivax malaria. This occurred directly as a 
result of concerns of the commercial sponsor (Lapierre and 
Duparc 2007), GlaxoSmithKline, that DH2000 makes the 
development of drugs for malaria prevention unethical (dis-
cussed later). Several other antimalarials might be considered 
as potential prophylactic agents if the DH2000-related ethical 
concerns are resolved. These include primaquine, weekly 
administered atovaquone-proguanil, azithromycin combina-
tions, and piperaquine. We refer the reader to several recent 
reviews for a comprehensive outline of their development 
status (Chen and Keystone 2005; Baird et al 2007) and to 
Table 2 for a summary of their advantages and limitations. 
Primaquine is included in this list since it has not yet been 
formally approved for continuous prophylaxis.
The traditional development 
of antimalarial drugs for treatment 
and prophylaxis
The traditional clinical development of antimalarial drugs 
is outlined in Figure 1 and below. Atovaquone-proguanil 
(MalaroneTM) is used as an example since it was the last drug 
approved for malaria treatment and prophylaxis in the USA 
(USFDA 2000). However, it is important to ﬁ  rst describe the 
general manner in which drugs are usually developed and 
approved. We have used the FDA-regulated process in the 
USA as an example below, and refer the reader elsewhere 
for more information (USCEDER 2007).
The ﬁ  rst step is the ﬁ  ling of an investigational new drug 
(IND) application with the FDA. The absence of any safety 
concerns triggers initiation of the clinical program. Firstly, 
Phase 1 clinical studies are conducted to demonstrate the 
safety, establish the maximally tolerated dose, and charac-
terize the pharmacology in normal healthy volunteers. Next, 
the potential efﬁ  cacy and tolerability of one or more doses of 
the drug is evaluated in a small number of patients in Phase 
II studies. Thereafter, the dose of drug that will be marketed 
for the desired indication is selected. A series of at least two 
‘pivotal Phase III’ studies are then conducted using this 
dose to demonstrate efﬁ  cacy and safety. If the data suggest 
a favorable risk:beneﬁ  t relationship, the sponsor then ﬁ  les 
a new drug approval (NDA) application, that, if approved, 
allows the drug to be marketed. Additional post-licensing or 
Phase IV studies may be required to further evaluate safety. 
Ideally, all clinical studies are conducted in the intended tar-
get population. It is normal practice to use placebo in Phase 
I studies. Placebo may also be used in Phase II and Phase 
III if no effective drugs are available, or in the interests of 
ensuring scientiﬁ  c validity.
In reality, the traditional development of antimalarial 
drugs differs from this idealized scenario in several respects. 
Firstly, pivotal Phase III prophylaxis efﬁ  cacy studies histori-
cally have not been conducted in the intended target popula-
tion. This is because placebo must be used in order to establish 
exposure to malaria, but the use of placebo is contraindicated 
in traveling nonimmunes because close medical supervision 
in most circumstances is usually not possible (discussed in 
more depth later). The alternative is to conduct the Phase 
III efﬁ  cacy studies in semi-immune populations in endemic 
countries, as was the case with Malarone® (Lell et al 1998; 
Shanks et al 1998; Sukwa et al 1999). Close medical supervi-
sion is more feasible in these endemic area populations. A 
key consequence of this approach is that prophylactic efﬁ  cacy 
cannot be proven in the traditional target population in the 
normal fashion. Rather, a series of additional supplementary 
nonpivotal studies are required. In the case of Malarone, these 
included two small challenge studies in nonimmune volun-
teers (Shapiro et al 1999; Berman et al 2001), a placebo-con-
trolled study in Indonesian trans-migrants (Ling et al 2002), 
and a comparator study in deployed South African soldiers 
(van der Berg et al 1999).
Secondly, in the case of blood schizonticidal drugs the 
Phase III prophylactic efﬁ  cacy studies may be preceded by 
a series of Phase II and III studies to prove efﬁ  cacy for treat-
ment of malaria. In the case of Malarone, this was necessary 
to select the appropriate partner drug for atovaquone, desired 
dosing regimes and to prove the efﬁ  cacy of the combination 
(see reviews by Looareesuwan et al 1999; Marra et al 2003; Therapeutics and Clinical Risk Management 2008:4(4) 807
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Boggild et al 2007). Without these studies, the develop-
ment of Malarone for prophylaxis would have been vastly 
more challenging. This is because the prophylaxis regimen 
employs the same combination partner:drug and drug:drug 
ratio deﬁ  ned during the prior treatment studies. Also, the 
treatment studies support the notion that the prophylaxis 
regimen will be effective despite limited direct evidence of 
this in the target population.
Finally, since the Phase III prophylactic efﬁ  cacy stud-
ies we conducted in small nontarget populations without 
direct comparison to conventionally used prophylaxis drugs, 
additional safety studies were required. In the case of Mal-
arone, two studies were conducted in nonimmune travelers 
using meﬂ  oquine and chloroquine-proguanil as comparators 
with tolerability as the primary endpoint (Hogh et al 2000; 
Overbosh et al 2001). Efﬁ  cacy was a secondary endpoint in 
these studies. Functionally, these studies represent a hybrid 
of traditional Phase III pivotal and Phase IV post-licensing 
studies. They showed that Malarone was well-tolerated in 
the intended target population compared to the available 
Table 2 Characteristics of future prophylaxis drugs
Drug Sources Likely Regimen Status Advantages Disadvantages
Primaquine Baird et al 1995; Weiss 
et al 1995; Sanoﬁ  -
Synthelabo 1999; Hill 
et al 2006
Daily Recommended, but not 
formally approved for con-
tinuous prophylaxis – used 
off-label for this purpose.
Inexpensive most juris-
dictions and approved 
for other indications.
G6PD test required. 
Daily administration 
required. Little intrinsic 
blood stage activity can 
lead to severe malaria 
rapidly if doses missed. 
Cannot be used in some 
populations without 
formal licensure.
Tafenoquine See accompanying text Weekly and/or pre-
exposure prophylaxis
Development for pro-
phylaxis halted due to 
DH2000 concerns. Indica-
tion switched to treat-
ment of P. vivax.
Long half-life and appar-
ent good activity against 
multi-drug resistant 
malaria. Activity against 
all parasite stages. Mul-
tiple modes of adminis-
tration possible.
G6PD testing will prob-
ably be required.
Weekly Malarone Shanks et al 1999; GSK 
2004; Edstein et al 2005
Weekly and/or pre-
exposure prophylaxis
Proof of concept study 
needed.
Potential indication 
supported by post-
treatment recrudescence 
patterns.
Efﬁ  cacy in a weekly 
mode unknown. Weekly 
regimen may not be 
sufﬁ  cient to suppress 
P. vivax blood stages. 
Resistant infections may 
emerge with shorter 
proguanil half-life.
Azithromycin Taylor et al 1999; Dunne 
et al 2005; Heppner et al 
2005b; Miller et al 2006; 
Noedl et al 2006
Daily-Weekly In development for treat-
ment* indication in com-
bination with chloroquine 
(and other antimalarials).
Approved drug and 
likely safe in children and 
pregnancy
Probable requirement 
for daily dosing. Incom-
plete (60%–90%) protec-
tive efﬁ  cacy against 
P. falciparum will require 
combination with other 
drugs, a higher dose, or a 
different formulation.
Piperaquine Davis et al 2005; 
Hasugian et al 2007
Weekly and/or pre-
exposure prophylaxis
Being developed for 
treatment indication in 
combination with dihydro-
artemisinin.
Long half-life and activity 
against CQ-resistant 
malaria. Suppression of 
reinfection in treatment 
trials strongly suggest 
that concept would 
work.
Safety proﬁ  le not fully 
characterized. Proof 
of concept studies for 
prophylaxis have not 
been done. Resistance 
may emerge rapidly with 
anticipated widespread 
use for treatment.
Note: *Intention of manufacturer is to develop azithromycin/chloroquine for IPT (Ritzhaupt et al 2007); All information was obtained from recent reviews or from the sources 
indicated in the accompanying text.Therapeutics and Clinical Risk Management 2008:4(4) 808
Dow et al
alternatives. This approach worked for Malarone, but might be 
more problematic for some drugs if tolerability and pharma-
cokinetic differences exist between the South-East Asian and 
African populations utilized during the Phase II/III program and 
the intended target population (mostly Western travelers).
In the context of DH2000, it is placebo, the utilization 
of semi-immune populations in the Phase III prophylaxis 
studies, and in the case of Malarone, and the sustainability 
of post-trial access to study drug, that raise ethical concerns. 
These issues are explored in depth in the next section.
DH2000 and its relevance 
to malaria prophylaxis
The 5th Amendment to the Declaration of Helsinki is dif-
ferent from its predecessors in several respects. Firstly, it 
claims under Paragraph 9, to be a universal statement of 
research ethics with primacy over similar documents (Lie 
et al 2004). Secondly, DH2000 substantially altered the lan-
guage of existing articles, and introduced new articles in an 
attempt to clarify issues thought to be inadequately addressed 
in prior amendments (Carlson et al 2004). These changes 
have provoked great controversy and we refer the reader 
elsewhere to detailed discussions of these issues (Reynolds 
2000; Simon 2000; Emmanuel and Miller 2001; Forster 
et al 2001; Carlson et al 2004; Lie et al 2004). However, 
DH2000 has also changed the ethical context with respect 
to three issues of critical importance to the development of 
new prophylactic antimalarial drugs. These relate to social 
beneﬁ  t (Paragraph 9), placebo controls (Paragraph 29) and 
post-trial access to study drug (Paragraph 30).
Traditional Clinical
Development
(eg, Malarone*)
Alternative #1
Western 
Travelers
Alternative #2
Endemic/Nonendemic
Non-immunes
Phase IIA
Phase IIB/III
Phase III/Post-
Licensure
SEMI-IMMUNES
Dose-ranging treatment
studies (comparator)
Multiple studies
N = 397
ENDEMIC 
SEMI-
IMMUNES
Prophylaxis
(placebo)
4 Studies
N = 842
ENDEMIC 
SEMI-
IMMUNES
Treatment
(comparator)
3 Studies
N = 1030
NON-IMMUNE
TRAVELERS/TRANSMIGRANTS/ 
SOLDIERS
Prophylaxis (comparator)
4 Studies, N = 2446
WESTERN 
NON-IMMUNES
Dose ranging 
challenge 
studies
(placebo)
N = HUNDREDS
WESTERN NON-IMMUNES
Challenge study (placebo)
N <= 50
WESTERN 
NON-IMMUNES
Prophylaxis
(comparator)
2 Pivotal studies
N = 32000
MONITORING
DH2000
Issues
Paragraphs 19 
(Benefit), 29 
(Placebo) and 30 
(Access)
BENEFIT: Semi-immune population from which volunteers 
are drawn do not benefit from prophylaxis indication. As a 
package all studies also support treatment indication from 
which endemic population may benefit. There is thus 
general benefit if drug is licensed in endemic countries for 
treatment and prophylaxis.
Direct benefit to study participants must be addressedin 
individual studies.
PLACEBO:NO CONCERNS AS EXECUTED.
ACCESS:High cost of goods made access to Malarone in 
endemic countries unsustainable.
Sponsor must have a comprehensive plan to address 
sustainable access. This may vary depending on the 
circumstances but must be approved by host country IRBs.
COMBINATION OF AT LEAST TWO 
STUDIES IN:
Various endemic or non-endemic country 
non-immune populations.
Exposure rates defined by placebo or 
biomarkers of exposure.
N = 360–4320 per study depending on 
design, location and attack rates (See 
Table 3)
Feasibility
N = 4751  –10 years
Feasible and results in 
two indications
N > 32000 
12–20 years
Unfeasible
N = 2860–4980, Optimistic = 5–7 years
Technical, logistical and regulatory 
challenges make conservative 
duration estimate difficult to define
NON-IMMUNE VOLUNTEERS
Prophylaxis challenge study 
(placebo)
1 Study, N = 20
NON-IMMUNE 
Challenge study
(placebo)
1 Study
N = 16
FOLLOWUP COMPARATOR STUDIES
 MIGHT BE REQUIRED IN NON-
IMMUNE TRAVELERS 
Alternative #3
IPT/Pre-exposure 
prophylaxis
NO DH2000 
CONCERNS
BENEFIT: Non-immune populations from which 
study participants are drawn can benefit directly 
from prophylaxis indication if drug is licensed in 
their country. Direct benefit to study participants 
must be addressed in individual studies.
PLACEBO:NO CONCERNS IF 
APPROPRIATELY EXECUTED.
ACCESS:Goal should be to make drug available 
at reasonable cost for prophylaxis in host 
countries. Sponsor should have a comprehensive 
plan to address sustainable access. This may vary 
depending on the circumstances but must be 
approved by host country IRBs.
ENDEMIC COUNTRY ADULTS
Dose-ranging treatment of 
uncomplicated malaria (comparator)
Multiple studies
N approx 400
NON-IMMUNE
ADULTS
Pre-exp versus 
standard 
prophylaxis
TWO Pivotal 
studies, N = 2000
NON-IMMUNE 
AGE DE-
ESACALATION 
STUDIES 
IPT (Comparator)
TWO Pivotal 
studies, N = TBD
MONITORING
N > 3200, time frame >10 years
Would likely require well tolerated blood 
schizonticidal drug combination
Feasibility unproven, three indications possible
BENEFIT: Non-immune populations from which study 
participants are drawn have clear potential benefit. 
General population in endemic countries may benefit 
directly from the treatment indication. The future 
availability of IPT for children/infants not possible w/out 
studies in adults. Direct benefit to study participants must 
be addressed in individual studies.
PLACEBO:NOT NECESSARY FOR BLOOD 
SCHIZONTICIDAL DRUG.
ACCESS:Goal should be to make drug available at 
reasonable cost for IPT in host countries. Sponsor 
should have comprehensive plan to address sustainable 
access. This may vary depending on the circumstances 
but must be approved by host country IRBs.
* Conducted prior to DH2000
ENDEMIC NON-IMMUNES
Dose ranging prophylaxis studies 
(placebo or biomarkers)
At least one study, N = 100–600
ENDEMIC COUNTRY ADULTS
Uncomplicated malaria pivotal treatment
             studies (comparator)
Multiple studies
N approx 800
Figure 1 Clinical development of new drugs for malaria prevention.
Note: Antimalarial drugs have traditionally been developed for both malaria treatment and prophylaxis as outlined in the panel on the left. Malarone, the last drug approved 
in the United States, and developed prior to the adoption of the 5th Amendment of the Declaration of Helsinki (DH2000), is used as an example. Major pharmaceutical 
companies now consider this approach to be unethical because placebos must be used and the Phase III prophylaxis studies utilize semi-immune individuals in malaria-endemic 
countries who would not normally beneﬁ  t from malaria prophylaxis. The development of MalaroneTM (atovaquone-proguanil) has also been criticized because the high cost of 
treatment made sustainable post-trial access to the drug difﬁ  cult. Our perspective is that the traditional approach remains ethical and consistent with DH2000 for the reasons 
stated at the bottom of the left panel and discussed in the accompanying text. The three panels to the right outline potential alternative clinical development pathways based 
on studies conducted in the traditional target population for prophylaxis (Western travelers), mixed populations of endemic country and nonendemic country immunes or 
focused on novel forms of prophylaxis. These resolve some of the DH2000 ethical concerns but have varying degrees of feasibility as indicated in the ﬁ  gure and discussed in 
the accompanying text.Therapeutics and Clinical Risk Management 2008:4(4) 809
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Primacy of the 5th Amendment:
Paragraph 9 of DH2000 (WMA 2004) states the following: 
“Research Investigators should be aware of the ethical, legal 
and regulatory requirements for research on human subjects 
in their own countries as well as applicable international 
requirements. No national ethical, legal or regulatory require-
ment should be allowed to reduce or eliminate any of the pro-
tections for human subjects set forth in this declaration”.
It is clear from this provision that the current version of 
the Declaration of Helsinki is intended to have priority over 
national laws and regulations (Forster et al 2001). The text 
differs substantially from the 1996 version, which states that 
“physicians are not relieved from criminal, civil and ethical 
responsibilities under the laws of their own countries” and 
that its provisions were intended to be “recommendations” 
(Forster et al 2001). In the past, it was possible to argue that 
the Declaration was a source of guidance, and research studies 
were ethical provided that they were approved by local institu-
tional review boards and were compliant with local laws and 
regulations. Now, it is possible to argue that a study is unethi-
cal because it is not ‘DH2000 compliant’, even if all local 
laws and regulations are followed. Consequently, individual 
researchers or national regulatory agencies protect themselves 
against uncertainty by publicly stating which version of the 
Declaration of Helsinki (or other ethical code) is to be fol-
lowed (Forster et al 2001; Riis 2003). For example, the US 
FDA requires that foreign clinical trials must be conducted to 
an ethical standard that is consistent with the 1989 version of 
DH or the laws and regulation of the host country, whichever 
provides the greatest protection (USFDA 2001).
In order to avoid any accusation of unethical behavior, it 
is almost inevitable that large multinational pharmaceutical 
companies would insist that their sponsorship of international 
research studies be conducted in accordance with both relevant 
national regulations and DH2000, whichever is more strin-
gent, and to avoid such endeavors where a conﬂ  ict exists.
Social beneﬁ  t
Paragraph 19 states the following: “Medical research is only 
justiﬁ  ed if there is a reasonable likelihood that the populations 
in which the research is carried out stand to beneﬁ  t from the 
results of that research” (WMA 2004). The provision is a new 
addition to the Declaration, and was intended to ensure that 
medical research is responsive to the needs of the population 
in which it is conducted.
In the context of Paragraph 19, the appropriateness of the 
three Malarone semi-immune prophylaxis studies, and, by 
extension, the traditional development paradigm itself have 
been challenged on the basis that the communities involved 
would be very unlikely to beneﬁ  t from this indication (Nosten 
2000). Prophylactic antimalarial drugs are not in widespread 
use in endemic countries (Nosten 2000). This is due to several 
factors, including the impracticality of their deployment on 
a long term basis to entire populations, concerns over devel-
opment of resistance, potential unknown risks of adverse 
events with long term usage, and the specter of a decline in 
the development of semi-immunity that may result if malaria 
prevention could not be sustainably provided.
Since prophylactic drugs are not usually indicated in 
semi-immunes for the reasons stated above, some pharma-
ceutical companies have concluded that there is no reasonable 
likelihood of beneﬁ  t and such studies are unethical (Lapierre 
and Duparc 2007).
Placebo controls
Paragraph 29 states that: “The beneﬁ  ts, risks, burdens and 
effectiveness of a new method should be tested against those 
of the best prophylactic, diagnostic, and therapeutic methods. 
This does not exclude the use of placebo, or no treatment, in 
studies where no proven prophylactic, diagnostic or thera-
peutic method exists” (WMA 2004).
The intention of this provision was to prevent a reoc-
currence of controversial placebo-controlled studies. An 
oft-cited example is the use of a placebo control in studies 
designed to determine the utility of HIV drugs for prevention 
of vertical transmission of HIV, despite the fact that proven 
treatments were available (La Vaque and Rossiter 2001). This 
provision sparked such controversy and great debate that the 
WMA issued a clariﬁ  cation in 2002, stating the circumstances 
under which a placebo control may be acceptable even if a 
proven therapeutic method exists:
“Where for compelling and scientiﬁ  cally sound method-
ological reasons its use is necessary to determine the efﬁ  cacy 
or safety of a prophylactic, diagnostic method; or where a 
prophylactic, diagnostic or therapeutic method is being inves-
tigated for a minor condition and the patients who receive 
placebo will not be subject to any additional risk of serious 
or irreversible harm” (WMA 2004).
Despite this clariﬁ  cation, the pharmaceutical industry have 
adopted the view point that the use of placebo is unethical 
in the context of Phase III malaria prophylaxis studies since 
effective drugs are available (Lapierre and DuParc 2007).
Post-trial access to prophylactic drugs
Paragraph 30 states that “at the conclusion of the study, every 
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to the best proven prophylactic, diagnostic and therapeutic 
methods identiﬁ  ed by the study” (WMA 2004).
At its meeting in France 2004, the WMA issued the fol-
lowing clariﬁ  cation to Article 30:
“The WMA hereby reafﬁ  rms its position that it is neces-
sary during the study planning process to identify post-trial 
access by study participants to prophylactic, diagnostic and 
therapeutic procedures identiﬁ  ed in the study or access to 
appropriate care. Post-trial access arrangements or other 
care must be described in detail in the study protocol so the 
ethical review committee may consider such arrangements 
during its review” (WMA 2004).
The intention of Article 30 was to prevent the withdrawal 
of study drug from subjects participating in clinical trials 
who would normally not have access to the study medication 
due to either expense or unavailability (see Blackmer and 
Haddad 2005). From the perspective of a potential sponsor, 
many aspects of this provision are problematic. As Blackmer 
and Haddad (2005) and Riis (2003) have outlined, the issues 
of scope and responsibility are not adequately deﬁ  ned. It is 
unclear whether the burden of providing post-trial access to 
treatment falls on the sponsor or the public health system 
of the country (Blackmer and Haddad, 2005). As pointed 
out by Riis (2003), the time frame of provision of access 
is also unclear: should this be until the product reaches the 
market, or does this mean indeﬁ  nitely? It is also unclear how 
Paragraph 30 should apply in a non-Phase III setting, where 
the study may prove nothing in terms of a new prophylactic 
method. Finally, it can also be argued that the requirement 
to provide access (Paragraph 30) also applies to the general 
population (Paragraph 19), since how can one reasonably 
beneﬁ  t if provisions are not made to ensure sustainable 
access? Indeed, if the principle of distributive justice is fol-
lowed to its logical conclusion, it may be reasonable to argue 
that failure to ensure in advance the reasonable availability 
of a future product in a timely manner to study participants 
and the populations from which they are drawn is sufﬁ  cient 
reason for a study to not be executed at all (discussed by 
Macklin 2001).
Once again, the Malarone example is insightful. The 
sponsor attempted to make Malarone available on a limited 
compassionate basis through the Malaria Donation Project 
(Shretta et al 2000, 2001). However, it is clear in retro-
spect that the high cost of making Malarone was always 
going to pose challenges in terms of ensuring sustained 
access (Shretta et al 2000, 2001). Post-trial availability 
was not discussed in the publications reporting the results 
of the prophylaxis studies (Shanks et al 1998; Lell et al 
1998; Sukwa et al 1999), presumably because they were 
conducted prior to DH2000. Therefore, it is unclear to 
what degree local institutional review boards were fully 
informed as to their implications. This underscores the 
point that a plan for sustainable access must be addressed 
a priori.
The most conservative strategy for a large, publicly-
owned pharmaceutical company to discharge the risk associ-
ated with the above ethical uncertainties would be to ensure 
that Phase III clinical development programs are not executed 
in endemic countries unless there is an a priori commitment 
from senior management to market the drug for the intended 
indication at a reasonable price.
Impact of DH2000 on clinical 
development of drugs for malaria 
prevention
As a consequence of the uncertainties raised by DH2000, 
many large pharmaceutical ﬁ  rms have adopted the follow-
ing mantra in order to manage ‘ethical’ risk: Compliance 
with the spirit of DH2000 can only be assured if a com-
mitment exists a priori, to register and make available at 
a reasonable cost, a speciﬁ  c compound, for the speciﬁ  c 
indication, in those countries in which the clinical program 
is executed and placebo cannot be used since effective 
drugs for prophylaxis exist. As a consequence, they have 
reached the conclusion that this burden cannot be met in 
the context of prophylactic drugs. They have ceased active 
involvement in development of drugs for this indication 
as a result.
Most companies active in the development of antima-
larial drugs today are doing so on a noncommercial basis. 
In this context, their focus is on the treatment indication, 
and many companies do provide the fruits of that research 
effort at or below cost to endemic countries. CoartemTM is 
an example of this (Novartis 2006). The value to a sponsor 
of such engagement is primarily the positive public proﬁ  le 
generated by tackling a neglected disease. There is thus very 
little incentive to risk being considered unethical by devel-
oping prophylaxis drugs with a small commercial market in 
nonendemic countries.
This is the central reality that must be engaged if one is 
to conceive of a pathway forward for the development of 
new prophylactic drugs. Whilst one can argue, as we will 
do, that alternative interpretations of the DH2000 can allow 
prophylactic drug development to occur in an ethical and 
DH2000 compliant manner, one must also reconsider the 
traditional development paradigm in light of this reality. Therapeutics and Clinical Risk Management 2008:4(4) 811
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These two issues are the central matters of interest in the 
remainder of this review.
Is the traditional development 
paradigm ethical and DH2000-
compliant?
Previously, we outlined the ethical case against the traditional 
development paradigm from a DH2000 perspective. However, 
it is reasonable to consider why it is necessary to comply with 
DH2000 at all. The authors of DH2000 intended it to be the 
primary source of ethical guidance. However, the basis of this 
claim can be challenged. Firstly, the legal basis of WMA’s 
claim of primacy is debatable (Forster et al 2001). DH2000 
is not a treaty, has not been ratiﬁ  ed by national governments 
and so is not legally binding. Secondly, the moral and practical 
necessity for such a claim is now arguably defunct (Forster 
et al 2001). This is because the Nuremburg Code and the 
original Declaration of Helsinki came into existence when 
no recognized code of international research ethics was in 
place. This is no longer the case, with the advent of strict 
regulatory guidelines in most jurisdictions. Riis (2003), one 
of the original authors of the DH, has argued that DH2000 
should serve as a subordinate code of ethics, and that national 
and regional statutes should take precedence. From our per-
spective, it seems logical that national regulations should be 
thus be considered the source of ethical guidance where a 
conﬂ  ict exists with DH2000, but that DH2000 could usefully 
be considered the primary source of guidance in jurisdictions 
that choose to adopt it as national policy, or where no source 
of ethical guidance exists. If you accept this argument, a 
clinical program can be considered ‘ethical’, if not DH2000 
compliant, provided that all appropriate local and international 
laws are followed. An important caveat is that the interests 
of vulnerable populations cannot be protected in jurisdic-
tions with weak national regulations, or in those that lack the 
institutional capability to allow the appropriate constitution of 
ethical review boards and oversight of medical research. This 
is certainly the case in some malaria-endemic countries.
Nevertheless, the fact remains that some national 
governments may elect to adopt DH2000 as national policy. 
Therefore, DH2000 concerns must be addressed in a substan-
tive way. The key issues that must be addressed are those 
of ‘placebo’, ‘social beneﬁ  t’ ‘access/sustainability’. With 
respect to the use of placebo, it is clear that the 2004 clari-
ﬁ  cation to Paragraph 19 suggests that the use of a placebo 
is appropriate, even if effective treatments exist, if there is 
a compelling methodological reason or the risk of severe 
or irreversible harm is low. Both qualiﬁ  cations apply in the 
context of malaria. A placebo controlled arm in Phase II 
challenge and Phase III ﬁ  eld studies is necessary for scientiﬁ  c 
and methodological reasons for the development of drugs 
for malaria prevention. In the context of a challenge study, 
a placebo arm is essential for demonstrating the infectivity 
of mosquitoes (Shapiro et al 1999; Berman et al 2001; Bejon 
et al 2005; Heppner et al 2005a; Wang et al 2005; Dunachie 
et al 2006; Walther et al 2006). In Phase III prophylaxis 
studies (eg, those that supported the licensure of Malarone) 
the use of placebo reduces the sample size required by 
several orders of magnitude. The effect of this is that the 
clinical development of a drug is potentially more logisti-
cally feasible, less expensive, and may result in more rapid 
approval and availability to populations who may beneﬁ  t. 
Placebo-controlled malaria challenge studies in nonimmunes 
are considered ethical (Miller and Grady 2003). Malaria, if 
rapidly diagnosed and treated, has minimal risk of severe or 
irreversible harm (Church et al 1997; Verhage et al 2005). 
Thus, placebo is appropriate in controlled settings where 
regular blood smears are examined to detect malaria, and 
the ensuing infection can be effectively treated with con-
ventional antimalarial drugs. Therefore, we would argue that 
the use of placebo controlled arms in clinical malaria studies 
is DH2000-compliant and should not be a concern from an 
ethical perspective, provided the studies are conducted in 
appropriate settings.
Paragraph 19 clearly states that a reasonable likelihood 
must exist that the populations in which the research is car-
ried out stand to beneﬁ  t from the results of that research. A 
reasonable interpretation of this language is that ‘populations’ 
does not refer only to study participants and that ‘reason-
able likelihood’ does not simply mean an abstract promise 
of beneﬁ  t in the future. The pharmaceutical industry have 
interpreted this to mean that prior to execution of a Phase III 
program, a sponsor must have the intent to license and market 
the drug in the country of interest for the speciﬁ  c indication 
being investigated. From our perspective this argument seems 
unnecessarily restrictive because (i) the concept of the ‘results 
of the research’ is not strictly deﬁ  ned under DH2000, (ii) 
sponsors make go/no go decisions at the level of the program 
rather than a speciﬁ  c study, and (iii) under the traditional 
paradigm, the clinical development of many drugs for the 
treatment and prophylaxis indications are linked. It is there-
fore reasonable, and consistent with the spirit of DH2000, 
to extend the concept of ‘results of the research’ to include 
the licensure of a drug for treatment as well as prophylaxis. 
Thus, development of a drug for malaria prophylaxis is 
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intent of the sponsor, a priori, is to develop and market a 
drug for prophylaxis and treatment. In this ideal scenario, 
the potential beneﬁ  t of the research for all (in endemic and 
nonendemic countries) can be maximized.
However, many aspects of clinical research fall outside 
this ideal. Speciﬁ  c examples are Phase I malaria challenge 
studies (eg, Shapiro et al 2002), the Phase II studies that 
identiﬁ  ed the appropriate combination partner for atova-
quone (reviewed by Looareesuwan et al 1999), or the Phase 
III studies that demonstrated the prophylactic efﬁ  cacy of 
primaquine (Baird et al 2001). In these instances, DH2000 
does not prescribe the appropriate beneﬁ  ts due the study 
population and participants. Indeed, in the context of a 
Phase I study, there is no beneﬁ  t to the study participants, 
and the possibility of general future beneﬁ  t remains theoreti-
cal. There are also no provisions under DH2000 to resolve 
ethical dilemmas created by uncertainties in the language of 
the document itself (Forster et al 2001). As pointed out by 
Macklin (2001), many of the ambiguities in DH2000 reﬂ  ect 
substantive ethical dilemmas that may never be resolved. 
There are two reasonable approaches that a sponsor may 
take and remain consistent with the spirit of DH2000. In 
the context of sustainable access (Paragraph 30, discussed 
later in this section), DH2000 mandates that an appropriate 
(ideally local) ethical review committee be presented with a 
comprehensive plan a priori. It would be logical to extend the 
same argument to an assessment of potential beneﬁ  t. Alter-
natively, as suggested by Riis (2003), one may use national 
or regional statutes or regulations as a source of guidance. 
Both approaches seem logical, ethical and consistent with 
the spirit of DH2000. An important caveat here is that many 
endemic countries do not have the institutional capability to 
execute robust independent ethical reviews. However, this 
is not true in many cases.
When considering benefit, one must remember that 
DH2000 is not the sole source of guidance. Shortly after the 
adoption of DH2000, a prestigious group of North American 
bioethicists and African clinician scientists proposed the 
‘fair beneﬁ  ts’ framework as an alternative to DH2000 (Anon 
2002). Both DH2000 and the fair beneﬁ  ts philosophy aim to 
avoid the exploitation of vulnerable populations, but address 
the issue of beneﬁ  t differently. Proponents of fair beneﬁ  t 
argue that beneﬁ  t to a community of study participants should 
be in proportion to the risks of the proposed research (Anon 
2002). Furthermore, the assessment of what constitutes a fair 
beneﬁ  t is a decision best left to those individuals or commu-
nities participating directly in the research (Anon 2002). For 
example, provision of needed healthcare for a community 
may be an acceptable beneﬁ  t for participation in a clinical 
trial. Conceptually, this approach sounds reasonable, but 
is unlikely to resolve the ethical risks for sponsors. In the 
context of a Phase III study involving a new antimalarial 
drug, the fair beneﬁ  ts approach is not consistent with the 
spirit of DH2000, since it leaves open the possibility that 
the study population will not beneﬁ  t from the study drug. 
Furthermore, whilst community consent to any program 
of research is desirable, this must also be accompanied by 
review and approval by an appropriately constituted ethical 
board in order to remain within the spirit of DH2000. Finally, 
proponents of the fair beneﬁ  ts philosophy leave unaddressed 
the concepts of equality and distributive justice. Thus, in 
our view, a sponsor is best able to remain consistent with 
the spirit of DH2000 if (i) the intent a priori is to market 
an antimalarial drug for as many indications of interest to 
host endemic countries as possible, and/or (ii) to provide 
an appropriate institutional review board the opportunity to 
review and assess the likelihood that beneﬁ  t would result 
from the research.
In terms of access, the pharmaceutical industry has inter-
preted collectively the provisions of Paragraph 19 and 30 to 
mean that a sponsor, when planning a Phase III program, 
must commit, a priori, to licensing and making available the 
study drug at reasonable cost, for the relevant indication, in 
the countries in which the study subjects were recruited. In 
the context of the traditional development paradigm, this 
would in most cases translate into provision of the study drug 
for malaria treatment and prophylaxis at cost. This seems 
reasonable in the context of an over-arching plan to develop a 
new drug, but may be inappropriate in some circumstances. It 
leaves unaddressed the issue of access for trial participants in 
the gap between trial termination and licensure. Furthermore, 
the development of antimalarial drugs is often not organized 
systematically by a single sponsor. Many antimalarial drugs 
have been shown to be effective for treatment or prophylaxis 
in ad hoc studies sponsored by different universities, travel 
clinics or other research institutions. Such institutions may 
not have the resources to commit to a donation or compas-
sionate use program. It may be reasonable to argue in such 
cases that the drugs concerned are already affordable, or, with 
the possible exception of atovaquone-proguanil, will become 
affordable once patent protection has lapsed and generic 
manufacturers enter the market. It is clear from the clariﬁ  ca-
tion to Paragraph 30 that the decision about what constitutes 
a reasonable ‘access’ plan is a decision intentionally left to 
local review boards, with the implication that not all boards 
will arrive at the same consensus on what is appropriate. Therapeutics and Clinical Risk Management 2008:4(4) 813
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Therefore, regardless of the circumstances, a sponsor can 
remain consistent with the spirit of DH2000, provided a plan 
to address sustainable access is approved by an appropriately 
constituted local review board.
Alternative clinical development 
paradigms
In the previous section, we argued that the traditional develop-
ment paradigm remains ethical under certain circumstances. 
Whilst we hope this case is persuasive, it is prudent to also 
consider alternatives. Alternative 1 would be to execute the 
entire clinical program in the traditional target population (see 
Figure 1). This approach would resolve all the ethical issues, 
but was rejected by the Malarone clinical development team. 
The stated reason was that the sample size (n = 16000 per 
study) required for each pivotal Phase III study was unfea-
sible. This is because this approach would have depended on 
measuring the superiority of the investigational drug compared 
to a standard drug with efﬁ  cacy (prevention of symptomatic 
malaria) as the primary endpoint (Hogh et al 2000), and the 
incidence of symptomatic malaria in patients taking effec-
tive prophylaxis is rare (Hogh et al 2000) and variable due 
to several factors (seasonality of malaria, travel destinations 
etc). In this section we explore two additional alternatives. 
Alternative 2 involves the use of nontraditional nonimmune 
populations where malaria exposure is estimated based on 
either placebo or through the use of biomarkers (see outline 
in Figure 1). Alternative 3 involves development of new drugs 
simultaneously for pre-exposure prophylaxis and IPT (see 
Figure 1). However, we must ﬁ  rst turn our attention to the use 
of biomarkers of exposure as alternative to placebo.
Use of biomarkers of exposure 
as an alternative to placebo
Currently, there are no established alternatives other than 
placebo to estimate malaria exposure and to control the size 
of a prophylaxis study. One can argue that a noninferiority 
design to demonstrate efﬁ  cacy might be appropriate since 
the concept of malaria prophylaxis is proven and effective 
regimes exist. However, the results of such a study are not 
interpretable if the expected attack rate is not observed in the 
comparator arm, because the study will be underpowered or it 
cannot be proven that exposure to malaria occurred. This is not 
hypothetical. A recent Phase III study conducted in Australian 
troops deployed to East Timor resulted in no incidences of 
symptomatic falciparum malaria in either the investigational 
drug or meﬂ  oquine (comparator) arms (Nasveld et al 2002a). 
Entomology and point prevalence studies of populations 
in the general area may not accurately predict exposure in 
transient populations in local areas because these popula-
tions behave differently. In addition, malaria epidemiology 
is highly localized (Greenwood 1989; Bautista et al 2006). 
Where close follow-up cannot be achieved, placebo cannot 
be used. Therefore, its use in travelers and deployed military 
personnel is unethical under most circumstances. A method to 
measure indirectly the exposure in individuals taking effective 
malaria prophylaxis would be ideal.
Validated biomarkers (surrogates) would not only obviate 
the need for a placebo, and the statistical requirement for large 
sample sizes in studies with cases coming from prophylaxis 
failures (see Table 3), but also facilitate execution in the 
target population. This would mitigate the ethical concerns 
with respect to both Paragraphs 19 and 29. Such a surrogate 
marker could be an antibody response, or a pattern of protein 
or gene expression. This approach has been demonstrated in 
principle by Orlandi-Pradines et al (2006) amongst French 
troops deployed to Gabon and Cote d’Ivoire. The soldiers 
were provided with a variety of insect repellants, protec-
tive devices such as bed nets as well as chemoprophylaxis. 
Around 35% of soldiers demonstrated an immune response 
to pre-erythrocytic antigens (CSP, LSA1, STARP, SALSA, 
and SR11.1), and the method was sensitive enough to detect 
differences in exposure between soldiers reporting different 
levels of compliance with entomological deterrent devices. 
CSP has long been used as a general marker of immunologic 
exposure to malaria (Druilhe et al 1986). Similar unpublished 
studies at WRAIR suggest that merozoite surface protein 
1 (MSP1) may have sufﬁ  cient sensitivity to justify further 
assessment for qualiﬁ  cation for use in regulatory studies 
(Ohrt et al 2007). In a regulatory context, these associations 
probably qualify some antibodies as potential biomarkers 
of exposure to malaria. However, none of the biomarkers 
discussed currently meet the regulatory burden required for 
them to be considered as validated biomarkers of exposure 
(Biomarker Deﬁ  nitions Working Group 2001; USFDA 2005, 
2007; Wagner et al 2007), so additional studies would be 
required to address this.
Nonimmune populations in endemic 
countries
The traditional target population for drugs for malaria pre-
vention is nonimmune travelers from nonendemic countries. 
However, any nonimmune individual traveling to an endemic 
area, including those from endemic countries, should take 
malaria prophylaxis if available to reduce the risk of death 
from malaria. They can therefore potentially beneﬁ  t from Therapeutics and Clinical Risk Management 2008:4(4) 814
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investigational drugs for malaria prevention. Examples of 
such populations are endemic country travelers, migrants, 
military members and university students. With the excep-
tion of university students, malaria prevention trials have 
been successfully executed in these populations in the past 
(three of many examples include Ohrt et al 1997; Ling et al 
2002; Walsh et al 2004). It is also important to recognize that 
the demographics of endemic countries are changing. The 
population of potentially traveling urban residents (mostly 
nonimmune) is increasing while that of rural residents 
(mostly semi-immune) is decreasing proportionally (UNFPA 
2007). Thus, drugs for malaria prevention may play a more 
important role in endemic countries in the future.
Phase III studies could be conducted in endemic country 
nonimmunes with a placebo, or using a biomarker approach. 
The sample sizes and challenges associated with various 
possible trial designs are outlined in Table 3. The principal 
advantage of utilizing such populations is that, in some cases 
(eg, university students or temporary migrants), they may be 
resident in endemic regions for an extended period of time. 
This means that the sample sizes required are much lower, 
because per person attack rates will be much higher than in an 
equivalent traveling population that might reside in the same 
region for a month or less. However, identifying appropriate 
populations may not be straightforward. Firstly, the popula-
tion should ideally be nonimmunes traveling temporarily to 
a region of higher endemicity (since permanent prophylaxis 
is not feasible they may not beneﬁ  t). Secondly, they must be 
traveling for sufﬁ  ciently long periods of time for the attack 
rate to approach 80% or more. Finally, if placebo must be 
used, the clinical context must allow the possibility of close 
follow up and rapid distribution of effective malaria treatment 
drugs. One other scientiﬁ  c concern with this approach is that 
the demographics of endemic nonimmunes may be differ-
ent from nonendemic country nonimmunes with respect to 
ethnicity, comorbidities etc. This may be problematic if phar-
macokinetics or tolerability are affected by these factors.
Safari studies
An alternative would be to conduct placebo controlled stud-
ies in nonimmune Western travelers or military personnel in 
endemic countries. One can envisage a scenario where nonen-
demic country volunteers would participate in a paid or subsi-
dized ﬁ  shing or safari trip to western Kenya or Tanzania and 
participate in a prophylaxis study. We term this approach the 
‘safari study’. This approach addresses the ethical concerns 
raised by Paragraphs 19 and 30. This approach differs from 
a comparable study in nonimmune Western volunteers, since 
it would not utilize a travel clinic population of volunteers 
already intending to travel, but would instead actively recruit 
study subjects to travel to a speciﬁ  c high transmission area. 
Consequently, this approach raises its own ethical concerns 
Table 3 Possible phase III-equivalent study designs
Population Design Surrogate 
markers?
Approximate 
sample size
Duration of 
exposure
Attack rate
(% per month)f
Challenges
Endemic nonim-
munesa
Placebo comparator 
test drug
No 360 3–6 months 13–27 Identiﬁ  cation of appropri-
ate populations.
Endemic nonim-
munes
Suppressive com-
parator test drug
Yes 720b 3–6 months 13–27 Identiﬁ  cation of appro-
priate populations. Bio-
marker not yet available.
Western travelers Suppressive com-
parator test drug
Yes 2160–4320c 1 month 13–27 Biomarker not yet avail-
able.
Western travelersd Comparator test 
drug
No 16000 2.5 weeks 1.2% Unfeasible due to large 
sample size.
Safari studiese Placebo comparator 
test drug
No 1080–2160c 1 month 13–27 Logistics and recruitment 
difﬁ  cult. Ethical issues 
due to potential for coer-
cement and exposure 
of participants to other 
vector borne diseases.
Notes: aStudy design based on WRAIR statistical modeling of a three arm prophylaxis study. Participants were to be randomized 1:1:3: to placebo:meﬂ  oquine:tafenoquine 
control, assuming an attack rate of 80% over a 3–6 month period. bSample sizes calculated assuming that exposure rates can be determined in a suppressive prophylaxis arm 
(meﬂ  oquine or doxycycline) using surrogate markers with 50% sensitivity. cApproximate sample sizes were determined by adjustment from the WRAIR study on the basis of 
anticipated exposure time and/or an assumed 50% sensitivity of surrogate markers in suppressive prophylaxis comparator arm. dStudy design from Hogh and colleagues (2000). 
eA placebo powered, natural challenge study conducted in nonimmune Western travelers recruited for study speciﬁ  c travel to high transmission areas of endemic countries. 
f   Total assumed attack rate was 80% over a three-six month period. This is equivalent to a 13%–27% monthly attack rate.Therapeutics and Clinical Risk Management 2008:4(4) 815
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(Table 3). Firstly, the airfares and local expenses of study 
participants would have to be compensated to a degree that 
some may consider coercive. Secondly, participation in the 
study would expose volunteers to infectious diseases that they 
would not otherwise encounter. Finally, it is reasonable to 
expect that study participants would be unwilling or unable 
to travel for prolonged periods. This would necessitate trips 
of shorter durations, lower per/person attack rates and pos-
sibly unfeasible sample sizes as a result.
The IPT/Pre-exposure prophylaxis 
paradigm
Intermittent presumptive treatment (IPT) is a strategy for 
using antimalarial drugs to minimize morbidity and mortality 
in high-risk populations living in malaria endemic areas by 
giving full treatment doses of drugs at deﬁ  ned time periods 
(Rosen et al 2004; Egan et al 2005; O’Meara et al 2005; 
Schellenberg et al 2006). For example, IPT in infants (IPTi) is 
being implemented in Sub-Saharan Africa to provide protec-
tion to infants between ages 0–12 months who suffer the high-
est malaria attributable mortality. In this setting, a treatment 
dose of a drug, most commonly sulfadoxine-pyrimethamine 
(SP), is given along with the age appropriate vaccines in the 
Expanded Program of Immunization (EPI).
Published results of studies show a modest protective 
effect against clinical attacks of malaria and severe anemia 
and very low rates of serious adverse events (Schellenberg 
et al 2001; Chandramohan et al 2005; Macate et al 2006). 
The overall-risk-beneﬁ  t and cost-beneﬁ  t of the intervention 
appears favorable, but there likely remain differences in 
effectiveness related to schedule of administration, age of 
dosing, differing levels of background SP resistance, use 
of other malaria control measures in the population such as 
insecticide treated bed-nets, transmission intensity, and other 
factors yet to be clearly deﬁ  ned. IPT can also be used in other 
vulnerable, high-risk populations such as pregnant women 
(IPTp), children ages 1–5 (IPTc), and for use in areas with 
intense but marked seasonal transmission (sIPTc).
Intermittent presumptive treatment is really the use of anti-
malarial drugs for a chemoprophylaxis indication in endemic 
populations at risk of malaria. Using chemoprophylaxis in 
endemic populations has historically been discouraged or not 
promoted because of fears of increased malaria morbidity and 
mortality after prophylaxis is discontinued (the “rebound” 
effect) and concerns over sustainability of the intervention 
(Greenwood et al 1995; Menendez et al 1997; Geerligs et al 
2003). The most recent experience with SP suggests that, at 
least with this drug, the rebound effect is not present or quite 
minimal and co-administering SP in the EPI vaccine sched-
ule is effective. In any case, because of IPT, the strategy of 
using antimalarial drugs for a chemoprophylaxis indication 
in endemic populations is increasingly an accepted practice 
in the appropriate setting. Therefore, the argument against 
testing drugs in endemic populations because the at risk 
population will never beneﬁ  t from the use of the drug with 
a prophylactic indication is not true.
Conceptually, IPT is analogous to pre-exposure pro-
phylaxis in nonimmune travelers. Recently, pre-exposure 
prophylaxis in nonimmune travelers was proposed as a new 
strategy for using antimalarial drugs to prevent infection in 
short term (less than one month) travelers (Shanks et al 2007). 
Full treatment regimes of antimalarial drugs would be given 
to travelers prior to their trip that would offer solid protection 
for the duration of travel. These drugs would need to be long 
acting agents, such as piperaquine, atovaquone, or tafenoquine, 
that could give reliable protection. This could be seen as a 
variation of “IPT for travelers”.
Thus, the needs of the nonimmune short term traveler and 
the needs of the relatively nonimmune very young endemic 
populations have begun to converge with the emergence of 
the IPTi strategy in Sub-Saharan Africa, and the pre-exposure 
prophylaxis strategy for travelers. Both groups would receive 
therapeutic doses of safe and well tolerated drugs to be given 
to asymptomatic populations at risk of serious morbidity and 
death due to malaria.
A hypothetical clinical trajectory to develop a drug 
simultaneously for IPT and pre-exposure prophylaxis is 
outlined in Figure 1. After appropriate dose ranging studies 
to establish an effective dose, pivotal comparator studies 
would be conducted in adults with uncomplicated malaria 
in endemic countries. These studies would utilize adequate 
clinical outcome as the primary endpoint and time to rein-
fection as the secondary endpoint. If safe and effective 
(primary and secondary endpoints), these studies would 
provide the rationale to execute pivotal, age de-escalation 
IPT studies in nonimmune children and infants. In paral-
lel, Malarone-like tolerability end-point studies could be 
conducted in which an IPT drug was compared to standard 
prophylaxis in nonimmune travelers. The execution of 
these studies would be contingent on the demonstration of 
adequate post-treatment reinfection patterns in the prior 
treatment studies.
This approach has several possible advantages. First, 
there is the prospect that a drug could be developed for two 
or three indications. Second, many industry-sponsor-related 
ethical concerns are resolved using this approach. Placebos Therapeutics and Clinical Risk Management 2008:4(4) 816
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would not be necessary for blood schizonticidal drugs devel-
oped in this manner, provided that the dosing regimes for 
all the Phase III studies remained unchanged. If the inten-
tion of the sponsor is to market the investigational agent at 
a reasonable price in the host country for IPTi/c, there is a 
reasonable likelihood of beneﬁ  t to the nonimmune pediatric 
population. The semi-immune adult population beneﬁ  ts 
because development of a potential drug for IPT for their 
children would not be feasible without their participation in 
the earlier treatment studies. Long term access to the drug 
will almost inevitably be more sustainable, since a sponsor 
might only be obligated to market the drug to the pediatric 
population in endemic countries.
There are several limitations to such an approach. First, 
as outlined, it is likely only to be applicable to a safe and 
very well-tolerated blood schizonticidal drug. Second, whilst 
rebound lack of immunity does not seem to be a problem 
so far for SP, this issue would need to be carefully thought 
through for a new drug. Third, this approach assumes that 
for prophylaxis, as for Malarone, regulatory agencies would 
accept a submission which did not include pivotal studies 
in the target population powered using efﬁ  cacy endpoints. 
Finally, it is currently unproven in practice, since no com-
mercially available antimalarials were developed for, and 
are currently used, for all these indications.
Clinical development of drugs 
for malaria prevention in a post-
DH2000 world
As we have seen, the 5th Amendment to the Declaration 
of Helsinki has changed the ethical environment in which 
drugs for malaria prophylaxis are developed. The traditional 
paradigm, in which antimalarial drugs are development for 
malaria treatment and prevention, is considered by some in 
the pharmaceutical industry to be unethical, due to concerns 
regarding the use of placebo, the perceived lack of reasonable 
likelihood of beneﬁ  t to some of the participating populations, 
and difﬁ  culties relating to ensuring sustainable post-trial 
access to the study drug. As we have shown, the required 
Phase III efﬁ  cacy studies in nonimmune Western travelers, 
the logical target population, are unfeasible, due to the 
large sample sizes required. Alternative development plans, 
including those that involve the use of biomarkers instead of 
placebo, nontraditional nonimmune populations rather than 
Western travelers, and/or intermittent preventative treatment 
are potential alternatives, but face formidable regulatory, 
technical and logistical obstacles. The Walter Reed Army 
Institute of Research (WRAIR) and other institutions are in 
the process of conducting the clinical and epidemiological 
studies and initiating the regulatory consultations that may 
resolve some of these issues. However, in the interim, the 
traditional development paradigm represents the most fea-
sible pathway forward.
How, then, should a sponsor proceed in a changed ethi-
cal environment? Our perspective as potential sponsors and 
codevelopment partners of future antimalarial drugs can 
be summarized as follows. Phase III prophylaxis studies in 
semi-immunes are clearly ethical under DH2000, provided 
that the intention of the sponsor is to market the drug for 
malaria indications of interest to host endemic countries. 
However, this ideal set of circumstances may not always 
prevail. In different situations, clinical studies may be 
considered DH2000 compliant on a case by case basis, if 
an appropriately constituted ethical review committee, in a 
country with the appropriate institutional capacity, is satisﬁ  ed 
that a reasonable likelihood exists of beneﬁ  t occurring as a 
result of the study. Furthermore, any clinical study or drug 
development plan is consistent with the spirit of DH2000 if 
an appropriately constituted local review board approves a 
comprehensive plan to address sustainable access a priori. 
Finally, the use of placebo is ethical and DH2000 compliant, 
since there are compelling scientiﬁ  c reasons for its use, and 
the risk of severe harm to study participants is minimal in the 
appropriate clinical context. The success of future efforts to 
develop drugs for antimalarial prophylaxis will ultimately be 
determined by how acceptable this view point is to important 
stakeholders such as the pharmaceutical industry, regulators, 
and host country institutional review boards. We hope that 
this perspective will be considered thoughtfully in the context 
of all the other factors that contribute to the feasibility of new 
antimalarial drug development.
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